×
About 855 results

ALLMedicine™ Chronic Anemia Center

Research & Reviews  264 results

Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients
https://clinicaltrials.gov/ct2/show/NCT04113187

Jun 14th, 2022 - Hereditary Hemorrhagic Telangiectasia (HHT) is a rare systemic autosomal dominantly inherited disorder of angiogenesis. Its major feature is the occurrence in 90% of patients of spontaneous and recurrent epistaxis responsible for iron deficiency a...

Diffuse Bone Marrow Involvement of Multiple Myeloma on 18FPSMA-1007 PET/CT: Is There a ...
https://doi.org/10.1097/RLU.0000000000004286
Clinical Nuclear Medicine; Michalski K, Jilg CA et. al.

May 28th, 2022 - A 71-year-old man presented with chronic anemia (hemoglobin 7.3 g/dL). Further serum analyses showed elevated prostate-specific antigen (13 ng/mL), suggestive of prostate cancer. However, ultrasound-guided transrectal sextant biopsy did not find a...

Pernicious Anemia Treatment & Management
https://emedicine.medscape.com/article/204930-treatment

May 16th, 2022 - Approach Considerations The following goals are the most important in establishing care for patients with pernicious anemia: To establish that the patient has cobalamin deficiency If there is evidence for folic acid deficiency but pernicious anemi...

Pernicious Anemia Differential Diagnoses
https://emedicine.medscape.com/article/204930-differential

May 16th, 2022 - Diagnostic Considerations By definition, pernicious anemia refers specifically to vitamin B12 deficiency resulting from a lack of production of intrinsic factor (IF) in the stomach. However, vitamin B12 absorption is a complex process, and other c...

see more →

Clinicaltrials.gov  47 results

Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients
https://clinicaltrials.gov/ct2/show/NCT04113187

Jun 14th, 2022 - Hereditary Hemorrhagic Telangiectasia (HHT) is a rare systemic autosomal dominantly inherited disorder of angiogenesis. Its major feature is the occurrence in 90% of patients of spontaneous and recurrent epistaxis responsible for iron deficiency a...

The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia
https://clinicaltrials.gov/ct2/show/NCT05018728

May 11th, 2022 - Sickle cell disease (SCD) is a genetic blood disorder that has profound effects on the brain. In the presence of chronic anemia, the brain microvasculature dilates in order to maintain adequate oxygen delivery to the tissue. As cerebral blood flow...

Observational Study for Patients With Hemoglobinopathies and Rare Inherited Anemia and Covid 19
https://clinicaltrials.gov/ct2/show/NCT04746066

May 5th, 2022 - The COVID-19 pandemic is causing many deaths around the world, putting a strain on health services. Patients with pre-existing chronic diseases are most affected by SARS-COV2 infection. Italy is one of the countries most involved. Thalassaemia, dr...

Role of the Radiologist in Management of Pulsatile Tinnitus
https://clinicaltrials.gov/ct2/show/NCT05338684

Apr 21st, 2022 - Tinnitus is a broad and complex subject concerning a symptom rather than a syndrome or a disease (1 ),New studies indicate that prevalence of tinnitus is 14.5% among those less than 40 years old and 17.5 - 35% among age over 40 years Old( 2-3 ). V...

Health Literacy - Neurocognitive Screening in Pediatric SCD
https://clinicaltrials.gov/ct2/show/NCT04917783

Apr 5th, 2022 - Pediatric sickle cell disease (SCD) is a blood disorder affecting approximately 70,000 to 100,000 individuals in the United States. Approximately 80% of individuals affected by SCD are African American, with approximately one out of every 346 indi...

see more →

News  31 results

FDA Grants Priority Review to Luspatercept-aamt for Non–Transfusion Dependent Beta Thalassemia
https://www.onclive.com/view/fda-grants-priority-review-to-luspatercept-aamt-for-non-transfusion-dependent-beta-thalassemia

Dec 3rd, 2021 - The FDA has granted priority review to the supplemental biologics license application (sBLA) for luspatercept-aamt (Reblozyl) for the treatment of anemia in adults with non–transfusion dependent (NTD) β-thalassemia. The European Medicines Agency h...

Luspatercept Benefit Also in Non-Transfusion-Dependent Thalassemia
https://www.medscape.com/viewarticle/952998

Jun 13th, 2021 - The first-in-class erythroid maturation agent luspatercept (Reblozyl) is already approved for the treatment of anemia in adult patients with beta thalassemia who require red blood cell (RBC) transfusions. Now it has also shown to be beneficial for...

How Fellows Can Add Value to Their Internal Medicine Residency Program
https://www.onclive.com/view/how-fellows-can-add-value-to-their-internal-medicine-residency-program

Dec 5th, 2020 - As hematology/oncology fellows, we work with colleagues from multiple specialties. However, the majority of our interactions are with the internal medicine service, so here we will help you to maximize the quality of your interactions with interna...

Fast Five Quiz: Are You Prepared to Confront Sickle Cell Disease?
https://reference.medscape.com/viewarticle/858964_6

Nov 2nd, 2020 - Urgent replacement of blood is often required for symptomatic anemia due to parvovirus B19 infection or acute splenic sequestration. Transfusions are not needed for asymptomatic chronic anemia or worsening anemia occurring during episodes of pain ...

Chronic Microaspiration and Frailty: A Geriatric Smoking Gun?
https://www.mdedge.com/fedprac/article/226990/hospital-medicine/chronic-microaspiration-and-frailty-geriatric-smoking-gun
Jonathan T. Stewart, MD, Vandan D. Kamath, MS, CCC-SLP et. al.

Aug 13th, 2020 - Frailty is a highly prevalent syndrome in nursing homes, occurring in at least 50% of patients. 1 The frailty phenotype has been described by Fried and colleagues as impairment in ≥ 3 of 5 domains: unintentional weight loss, self-reported exhaustio.

see more →